ADDERALL 10 Drug Patent Profile

When do Adderall 10 patents expire, and when can generic versions of Adderall 10 launch?

Adderall 10 is a drug marketed by Teva Womens and is included in one NDA.

The generic ingredient in ADDERALL 10 is amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate. There are fifty-five drug master file entries for this compound. Twenty-eight suppliers are listed for this compound. Additional details are available on the amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate profile page.

Summary for ADDERALL 10

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	40
Patent Applications:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ADDERALL 10
DailyMed Link:	ADDERALL 10 at DailyMed

Recent Clinical Trials for ADDERALL 10

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Boston Children's Hospital	Phase 1
Eva Szigethy	Phase 4
The Beckwith Institute	Phase 4

See all ADDERALL 10 clinical trials

US Patents and Regulatory Information for ADDERALL 10

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva Womens	ADDERALL 10	amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate	TABLET;ORAL	011522-007	Feb 13, 1996		DISCN	Yes	No

Expired US Patents for ADDERALL 10

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Teva Womens	ADDERALL 10	amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate	TABLET;ORAL	011522-007	Feb 13, 1996

International Patents for ADDERALL 10

See the table below for patents covering ADDERALL 10 around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	2003504406
Australia	6089200
World Intellectual Property Organization (WIPO)	0105407
European Patent Office	1202739
Mexico	PA02000290	FORMA DE DOSIFICACION ORAL DE LIBERACION INMEDIATA RAPIDA. (RAPID IMMEDIATE RELEASE ORAL DOSAGE FORM.)
Canada	2378336

ADDERALL 10 Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory of Adderall

Introduction

Adderall, a prescription medication primarily used to treat Attention Deficit Hyperactivity Disorder (ADHD) and narcolepsy, has been a significant player in the pharmaceutical market. Here, we delve into the market dynamics and financial trajectory of Adderall, exploring its current state, future projections, and the factors influencing its market.

Market Size and Growth

The global Adderall drug market has been experiencing steady growth, driven largely by the increasing prevalence of ADHD. As of 2023, the market size was approximately USD 20.90 billion and is projected to grow at a Compound Annual Growth Rate (CAGR) of 4% between 2024 and 2032, reaching a value of around USD 29.75 billion by 2032[1][3].

Key Drivers of Market Growth

Several factors are driving the growth of the Adderall market:

Increasing Prevalence of ADHD

The rising prevalence of ADHD is a primary driver. About 4% of adult Americans deal with ADHD symptoms daily, with males being three times more likely to be diagnosed than females[1].

Senior Population and Neurological Illnesses

The increasing senior population, which is more vulnerable to neurological illnesses such as Alzheimer's, also contributes to the market growth. The use of cognitive medicines for improved physical and mental performance further boosts demand[1].

Advanced Healthcare Infrastructure

Regions like North America, Europe, and the Asia Pacific benefit from advanced healthcare infrastructure, which facilitates the diagnosis and treatment of ADHD, thereby driving market growth. North America currently dominates the market, followed by Europe and the Asia Pacific[1][3].

Market Segmentation

The Adderall market is segmented by region and formulation:

Regional Segmentation

• North America: Dominates the market due to high ADHD prevalence and advanced healthcare infrastructure.
• Europe: Significant market with key players and increasing investment in research and development.
• Asia Pacific: Expected to grow at the highest CAGR due to increasing awareness about ADHD and rising healthcare expenditure[1][3].

Formulation Segmentation

• Immediate-Release and Extended-Release: Adderall is available in both forms, with the dosage and frequency determined by symptom severity and patient response[3].

Challenges and Limitations

Despite the growth, the Adderall market faces several challenges:

Ethical Concerns

Ethical concerns about the use of stimulant medications can limit market growth. These concerns include the potential for abuse and long-term side effects[1].

Price Increases and Shortages

Recent years have seen significant price increases for ADHD medications, including Adderall. The average price of certain ADHD medications has nearly doubled or tripled since the Adderall shortage began in October 2022. For instance, the price of Adderall XR 10mg increased dramatically from $10 to $158 in a short period[2].

Supply Chain Disruptions

The COVID-19 pandemic has caused disruptions in the supply chain and manufacturing activities, contributing to the current shortage of Adderall and other ADHD medications. Telehealth during the pandemic led to an increase in prescriptions, exacerbating the supply-demand imbalance[4].

Financial Impact on Patients and Families

The financial implications of ADHD and its treatment are substantial:

Cost of Medication

Without insurance, the cost of Adderall and other ADHD medications can be prohibitive. For example, a supply of 100 capsules of 10mg Adderall XR can cost around $759.54, and 100 tablets of 5mg short-acting Adderall can cost around $1,139[2].

Long-Term Financial Deficits

Adults with a history of childhood ADHD often face significant financial deficits, including lower income, reduced savings, and increased dependence on parents or public assistance. This translates to approximately $30 billion in lost income annually in the U.S.[5].

Strategies for Affordability

Given the high costs, several strategies are being employed to make ADHD medications more affordable:

Insurance Coverage

Insurance coverage is a critical factor for many patients. For 19% of respondents in a recent Medscape survey, insurance coverage was the most important factor in choosing an ADHD medication[2].

Manufacturer Coupons and Pharmacy Assistance

Some patients have found relief through manufacturer coupons and pharmacy assistance programs. For instance, a patient's copay was reduced to $35 per month with the help of a doctor and pharmacist who utilized manufacturer coupons[2].

Future Outlook

The Adderall market is expected to continue its growth trajectory, driven by increasing demand for effective ADHD treatments. Here are some key points for the future:

Recovery from Pandemic Disruptions

The market is expected to recover from the disruptions caused by the COVID-19 pandemic, with a focus on restoring supply chain stability and meeting the increased demand for ADHD medications[3].

Regional Growth

The Asia Pacific region is expected to grow at the highest CAGR, driven by increasing awareness about ADHD and rising healthcare expenditure[3].

Innovation and Research

Key players in the market are focusing on developing new drugs and therapies to strengthen their market position. This includes investments in research and development to address the evolving needs of ADHD patients[3].

Key Takeaways

• The global Adderall market is projected to grow at a CAGR of 4% from 2024 to 2032.
• The market is driven by the increasing prevalence of ADHD and the growing adoption of stimulant medications.
• North America dominates the market, followed by Europe and the Asia Pacific.
• Ethical concerns, price increases, and supply chain disruptions are significant challenges.
• The financial impact of ADHD on patients and families is substantial, with long-term financial deficits common among adults with a history of childhood ADHD.
• Strategies such as insurance coverage, manufacturer coupons, and pharmacy assistance are crucial for making ADHD medications more affordable.

FAQs

Q: What is the current market size of the Adderall drug market? A: As of 2023, the global Adderall drug market size was approximately USD 20.90 billion[1].

Q: What is the projected growth rate of the Adderall market? A: The market is expected to grow at a CAGR of 4% between 2024 and 2032[1][3].

Q: Which region dominates the Adderall market? A: North America dominates the Adderall market, followed by Europe and the Asia Pacific[1][3].

Q: What are the primary drivers of the Adderall market growth? A: The primary drivers include the increasing prevalence of ADHD, the growing senior population, and the benefits of cognitive medicines[1].

Q: How have recent price increases affected ADHD medication costs? A: Certain ADHD medications have seen their prices nearly double or triple since the Adderall shortage began in October 2022[2].

Sources

1. Expert Market Research - Adderall Drug Market Size, Share | Industry Statistics 2032
2. ADDitude - ADHD Medication Costs Soar: Price Report
3. Research and Markets - Adderall Drug Market Report and Forecast 2023-2031
4. PBS NewsHour - A 'perfect storm' led to an ADHD medication shortage. Here's why
5. FIU News - Financial gap between adults with childhood ADHD and those without, widens over time